$NTRA

RABINOWITZ DANIEL sold $4.6M of NTRA

RABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 16,800 shares of Natera, Inc. (NTRA) at an average of $272.29 ($266.79–$278.77, $4.57M total) across 12 trades on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RABINOWITZ DANIEL
Published Jul 7, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosed sale (~16,800 shares; weighted avg ~$272.29) can influence short-term sentiment, but the 10b5-1 structure reduces interpretability as a directional signal.

02

Market read

Traders may monitor for follow-on insider activity, but there is no new fundamental catalyst in the text.

03

What to watch

The article does not disclose any concurrent buy/sell by other insiders, nor any new guidance/clinical/regulatory update—so the signal is mostly sentiment/positioning, not valuation.

Relevance 5/10Novelty 5/10Timing: after-hours/next-session read-through from the latest Form 4 filing (filed 2026-07-06)

Background

The article is a primary-source SEC Form 4 insider transaction for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera Form 4 shows Daniel Rabinowitz (Chief Legal Officer) sold ~$4.57M of NTRA shares via an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any move would be more sentiment/flow-driven than fundamental.

Evidence & confidence

The filing is a routine Form 4 open-market sale with a pre-arranged 10b5-1 plan, and the article provides no new company-specific operational or financial catalyst.

Market effects

Minimal; insider-sale disclosures typically do not reset sector expectations without accompanying fundamental news.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish information.

Key entities

  • Natera, Inc.

    Company whose shares were sold by an insider (Chief Legal Officer) under a 10b5-1 plan.

  • Daniel Rabinowitz

    Chief Legal Officer who executed the open-market sale disclosed on Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.